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Abstract
Background: Triple negative breast cancer (TNBC) is a breast cancer subgroup characterized by a lack of hormone
receptors’ expression and no HER2 overexpression. These molecular features both drastically reduce treatment
options and confer poor prognosis. Platinum (Pt)-salts are being investigated as a new therapeutic strategy. The
base excision repair (BER) pathway is important for resistance to Pt-based therapies. Overexpression of APE1, a
pivotal enzyme of the BER pathway, as well as the expression of NPM1, a functional regulator of APE1, are
associated with poor outcome and resistance to Pt-based therapies.
Methods: We evaluated the role of NPM1, APE1 and altered NPM1/APE1 interaction in the response to Pt-salts
treatment in different cell lines: APE1 knockout (KO) cells, NPM1 KO cells, cell line models having an altered APE1/
NPM1 interaction and HCC70 and HCC1937 TNBC cell lines, having different levels of APE1/NPM1. We evaluated the
TNBC cells response to new chemotherapeutic small molecules targeting the endonuclease activity of APE1 or the
APE1/NPM1 interaction, in combination with Pt-salts treatments. Expression levels’ correlation between APE1 and
NPM1 and their impact on prognosis was analyzed in a cohort of TNBC patients through immunohistochemistry.
Bioinformatics analysis, using TCGA datasets, was performed to predict a molecular signature of cancers based on
APE1 and NPM1 expression.
Results: APE1 and NPM1, and their interaction as well, protect from the cytotoxicity induced by Pt-salts treatment.
HCC1937 cells, having higher levels of APE1/NPM1 proteins, are more resistant to Pt-salts treatment compared to
the HCC70 cells. A sensitization effect by APE1 inhibitors to Pt-compounds was observed. The association of NPM1/
APE1 with cancer gene signatures highlighted alterations concerning cell-cycle dependent proteins.
Conclusions: APE1 and NPM1 protect cancer cells from Pt-compounds cytotoxicity, suggesting a possible
improvement of the activity of Pt-based therapy for TNBC, using the NPM1 and APE1 proteins as secondary
therapeutic targets. Based on positive or negative correlation with APE1 and NPM1 gene expression levels, we
finally propose several TNBC gene signatures that should deserve further attention for their potential impact on
TNBC precision medicine approaches.
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Background
Breast cancer (BC) is a heterogeneous disease compris-
ing several biologically different subtypes characterized
by distinctive prognosis and potential therapeutic targets
[1, 2]. Although gene expression profiling technologies
are capable to finely describe four main intrinsic sub-
types, the logistic issues in deploying this methodology
in common clinical practice has resulted in the wide-
spread adoption of their immunohistochemistry (IHC)-
defined approximation, which is still capable of predict-
ing clinical outcome, pattern of metastatization and
benefit from distinct types of therapy [3–7]. Among BC
subtypes, triple negative breast cancer (TNBC) repre-
sents a challenge because of its heterogeneity and the
absence of a well-defined druggable target, restricting
clinical decision making to chemotherapy [8–10]. Differ-
ent approaches have been explored to better dissect the
TNBC profile in order to optimize therapeutic choices
and exploit new strategies, such as genotoxic agents and
interference with different DNA repair pathways [11,
12]. Among the therapeutic options already employed in
the clinical practice of several tumors including TNBC,
platinum (Pt)-based compounds emerge for their ability
to interfere with several cellular processes, including
DNA replication and transcription [13–15]. The most
common Pt-salts include cisplatin (CDDP), carboplatin
(CBDCA) and oxaliplatin [16]. Of note, the activity of
the single agent CBDCA was investigated through the
randomized phase III trial TNT. After a median follow-
up of 11 months, no significant improvements were ob-
served in the total population in terms of overall re-
sponse rate (ORR) with CBDCA versus docetaxel.
However, in patients with a germline BRCA1/2 muta-
tion, ORR was more than two-fold higher when treated
with CBDCA, with a longer progression-free survival
(PFS) [17]. Regarding the molecular effects of Pt-salts,
although several mechanisms of action were hypothe-
sized and are still under investigation, the most accre-
dited is the generation of mono-adducts, intra-strand
and inter-strand (ICL) DNA cross links, able to distort
the DNA backbone causing the formation of toxic single
(SSB) and double (DSB) strand breaks [16]. If not effi-
ciently repaired, DNA damages induced by Pt-salts may
cause an extensive blockage of the physiological cellular
processes, including DNA replication and transcription,
resulting, to an ultimate extent, in cell cycle arrest and
apoptosis. The preferable DNA repair pathways acting in
repairing bulky lesions induced by Pt-salts are the nu-
cleotide excision repair (NER), the homologous recom-
bination (HR) and the Fanconi anemia (FA) pathways
[18, 19]. Just recently, a role of base excision repair
(BER) pathway has been also hypothesized [19–21]. Typ-
ically, BER is active in repairing non-bulky DNA lesions
induced by oxidative, alkylating or methylation stressors
[22]. Upon the recognition of the damaged base by spe-
cific glycosylases, the apurinic/apyrimidinic endonucle-
ase 1 (APE1, also known as REF-1) cleaves the newly
generated abasic site allowing the accomplishment of
the DNA repair [23]. The pivotal role of APE1 is demon-
strated by its function in cellular viability and embryonic
development [24], due to its role in DNA repair activity
and other recently characterized non-canonical func-
tions. In fact, APE1 also plays an important role as redox
effector on many transcriptional factors, such as NF-κB,
HIF-1α, STAT-3, PAX8, AP-1 and p53 [23–27], regulat-
ing important genes involved in tumor progression.
Moreover, new interesting molecular functions involved
in RNA metabolism were recently discovered in our la-
boratory [23], including processing of damaged RNA
[28], miRNAs [29] and abasic and oxidized ribonucleo-
tides embedded in DNA [30]. The different functions of
APE1 are finely modulated by expression, localization,
posttranslational modifications (PTMs) [31–36] and by
its protein-protein interactome, as well. Indeed, APE1
localizes into the nucleus with a peculiar nucleolar accu-
mulation, which depends on active rDNA transcription
[37–41], but the precise significance of this subnuclear
distribution is currently non-completely clear [42]. Inter-
estingly, a proper shuttling from nucleoli to nucleoplasm
is essential for an efficient response to genotoxic damage
[43]. Up to now, it is well accepted that APE1 subcellu-
lar localization changes are associated with several cellu-
lar functions, as well as to cancer onset and progression
[28, 31, 41]. Interestingly, one of the major determinants
of APE1 accumulation within nucleoli is its interaction
with nucleophosmin (NPM1), which is modulated by
APE1 acetylation [41, 44]. NPM1 is a phosphoprotein,
which canonically acts as a central factor in rRNA gene
processing and as a chaperone in ribosome biogenesis
involved in cell proliferation [45, 46]. Depending on the
cellular context, NPM1 may act both as a proto-
oncogene and as a tumor suppressor and its perturba-
tions are often involved in tumorigenesis and cancer
progression [47, 48]. The NPM1 gene is also involved in
several chromosomal translocation characterizing several
tumors and involving genes such as ALK, RAR and
MLF1 [49]. In addition, an aberrant overexpression of
the NPM1 protein is another causing factor of several
tumors including colon and ovarian cancers [48, 50, 51].
Notably, its localization has an impact on tumorigenesis.
Indeed, NPM1 prevalently localizes within the nucleoli,
but it constantly shuttles between the nucleus and the
cytoplasm [45, 46, 52, 53]. We have already demon-
strated that NPM1, and its localization, have an impact
on BER activity. In fact, NPM1 is an important func-
tional regulator of BER factors, specifically controlling
levels and localization of BER proteins, including APE1
[43]. Moreover, in acute myeloid leukemia (AML)-
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associated mutations, the mutated NPM1 gene deter-
mines the formation of an aberrant NPM1 protein
(NPM1c+) which re-localizes in the cytoplasm. This
mis-localization hampers canonical functions of NPM1
[54–56] and affects APE1 nuclear BER function in can-
cer cells, through relocalization of APE1 itself in the
cytoplasm [41]. Finally, it has been demonstrated that
higher levels of APE1, often detected in several cancers,
confer acquired resistance to chemotherapeutic agents
[57] and that hyperacetylation of APE1 is associated with
the TNBC phenotype [31]. For these reasons, APE1 is an
emerging promising therapeutic target for cancer treat-
ment [58]. To this aim, research has been recently fo-
cused on the interference of APE1 functions, including
the AP-endonuclease function (e.g. Compound #3) and
the redox function (e.g. APX3330) [59, 60] (Codrich et
al., submitted), and on efficiently disrupting the APE1/
NPM1 interaction, such as SB206553, Fiduxosin and
Spiclomazine [61]. One of our purposes was testing
whether the treatment with BER inhibitors could
sensitize cancer cells to genotoxic agents [61]. Although
partially investigated, the relationship between BER and
Pt-salts needs to be further explored [20, 21, 62–68].
Based on the above mentioned evidences, we deemed
fundamental to investigate the cytotoxicity induced by
the combined treatment of Pt-compounds and APE1-
inhibitors, which may have synergistic therapeutic effects
in the treatment of cancers such as TNBC [69, 70].
For this reason, starting from the emerging import-
ance of Pt-salts for the treatment of TNBC patients and,
in parallel, from the continuously evolving knowledge on
APE1 functions, the purpose of this study was to under-
stand the role of APE1, and of its interactor NPM1, in
TNBC cell lines treated with Pt-compounds, including
CDDP and CBDCA. Specifically, by using different can-
cer cell lines and specific NPM1- or APE1- gene knock-
out cell models, we explored: i) the protective role of
APE1 and NPM1 in CDDP cytotoxicity and ii) whether
the APE1 and NPM1 proteins were modulated in terms
of level and subcellular localization upon Pt-compounds
treatment in TNBC cancer cells. Moreover, we investi-
gated whether targeting APE1 endonuclease activity or
its interaction with NPM1 may sensitize TNBC cancer
cells to Pt-compounds treatment. To corroborate our in
vitro data, we also considered APE1 and NPM1 levels in
a real-world cohort of patients affected by TNBC and
explored their potential prognostic impact for further
hypothesis-generation and potential clinical utility. Fi-
nally, we analyzed the TCGA-BRCA dataset (n = 1105),
focusing in particular on TNBC patients (n = 180), and
identified several gene signatures whose expression
levels correlated in a positive or negative way with APE1
and NPM1 expression. Notably, we examined the differ-
ences in patients that had an overall survival above/
below 5 years, or that underwent disease recurrence
after at least 1 year from diagnosis, highlighting the
genes and the underlying molecular processes that may
be involved in this different outcome.
Methods
Cell culture and transfection, chemicals and viability
assays
HCC70 and HCC1937 breast cancer cells (from ATCC®,
Sigma, Milan, Italy) and mouse embryonic fibroblast
(MEF) expressing (MEF NPM1+/+) or not NPM1 (MEF
NPM1−/−) [71], were cultured in RPMI 1640 supple-
mented with 10% (vol/vol) fetal bovine serum (FBS).
HCC70 cells carry a germline mutation (R248Q) in the
DNA binding domain (DBD) on the P53 protein and
present a wild type BRCA1 gene, whereas HCC1937
cells have an acquired mutation (C306T) occurring near
the tetramerization domain of P53 (amino acids 324–
359) and are homozygous for the BRCA1 5382insC muta-
tion. HCT116 colon cancer cells (from ATCC®, Sigma,
Milan, Italy) were cultured in DMEM High Glucose sup-
plemented with 10% (vol/vol) FBS; OCI-AML2 and 3
were cultured in α-MEM supplemented with 20% (vol/
vol) FBS [41]; CH12F3 cell lines were cultured in RPMI
1640 supplemented with 10% (vol/vol) FBS, 50 μM β-
mercaptoethanol and 25mM HEPES [72]. All culturing
media were also supplemented with 100 U/ml penicillin,
100 mg/ml streptomycin sulphate and 2mM l-glutamine
(EuroClone, Milan, Italy). Transfection of HCC70 cells
with FLAG-NPM1 plasmid was performed as explained
in [41]. Compound #3 and APE1/NPM1 inhibitors [61]
were dissolved in dimethyl sulfoxide (DMSO) as 10 mM
stock, cisplatin was dissolved in dimethylformamide
(DMF) as 33.3 mM stock and carboplatin was dissolved
in water as 13.45 mM stock (SIGMA, Milan, Italy). For
the MTS viability assay, 5.0 × 103 cells per well were
seeded in 96-well plates and grown for 24 h. After the
described treatment in 80 μl, cell viability was measured
by using the MTS assay (CellTiter 96® AQueous One So-
lution Cell Proliferation Assay – Promega, Milan, Italy)
and a multiwell reader. Values were read at 490 nm of
absorbance and were standardized to wells containing
media alone. Cell viability of both OCI-AML and
CH12F3 lymphocytes was measured as described in [72].
Differences in viability were analyzed through the Stu-
dent’s t-test using the GraphPad Prism software. Results
were considered statistically significant when p < 0.05.
IC50 values of each tested drug, and Bliss analysis in
combined treatments as well, were obtained by using the
Combenefit 2.021 software.
Preparation and quantification of cell extracts
For the preparation of whole cell extracts, cells were
harvested by trypsinization and centrifuged at 1000 rpm
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for 5 min at RT. The supernatant was removed and the
pellet was washed once with ice-cold phosphate-
buffered saline (PBS) and then centrifuged again. Cell
pellet was re-suspended in lysis buffer containing 50
mM Tris HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA and
1% (wt/vol) Triton X-100 supplemented with 1 mM pro-
tease inhibitor cocktail (Sigma, Milan, Italy), 0.5 mM
phenylmethylsulfonyl fluoride (PMSF), and cooled in ice
for 10 min. After centrifugation at 13,000 x g for 20 min
at 4 °C, the pellet was discarded while the supernatant
conserved at − 20 °C. The protein concentration was de-
termined using the Bio-Rad protein assay reagent (Bio-
Rad, Hercules, CA), using BSA (SIGMA, Milan, Italy) as
normalizer.
Western blotting analysis
To evaluate the protein levels at basal and treated condi-
tions, 15 μg of whole cell extracts were run in a 12%
SDS-PAGE gel. Proteins were then transferred to nitro-
cellulose membranes (Schleicher & Schuell, Keene, NH).
Membranes were saturated by incubation for 1 h at RT
with 5% (wt/vol) nonfat dry milk in PBS–0.1% (wt/vol)
Tween-20 and then incubated o/n with monoclonal
APE1 (NB 100–116 Novus Biologicals, Littleton, CO,
USA), a polyclonal NPM1 (ab15440 Abcam, Cambridge,
UK), a monoclonal NPM1c+ [41] and a monoclonal
FLAG (F1804, Sigma, Milan, Italy) at 4 °C. After three
washes with PBS–0.1% (wt/vol) Tween-20, membranes
were incubated with a IRDye800 labelled secondary anti-
bodies (diluted to 1:10000) for 1 h at RT. Finally, the
membranes were washed three times with PBS–0.1%
(wt/vol) Tween-20 and the blots were developed using
Odissey® CLx Imager (Li-Cor GmbH, Germany) and
quantified using Image Studio™, version 5 (Li-Cor
GmbH, Germany). Monoclonal β-tubulin (T 0198
SIGMA, Milan, Italy) and polyclonal β-actin (A 2066
SIGMA, Milan, Italy) proteins were used as normalizers.
Protein levels were analyzed through the Student’s t-test
using the GraphPad Prism software. Results were con-
sidered statistically significant when p < 0.05.
Cohort design and statistical analysis
We retrospectively analyzed a cohort of 111 consecutive
TNBC patients, treated between 2000 and 2014 at the
Department of Oncology of the University Hospital of
Udine, Italy. Cases were eligible independently from
stage at diagnosis, but patients with a history of second-
ary malignancy within the last 3 years were not included
in the analysis, except for adequately treated basal cell or
squamous cell skin cancer, or carcinoma in situ of the
cervix. Individual data and information on primary and
advanced disease were collected from electronic health
records and treated anonymously according to strict
privacy standards. The study was evaluated and
approved by the Regional Ethics Committee; protocol
number 27835. Correlations between cellular levels of
cytoplasmic APE1, nuclear APE1 and NPM1 were inves-
tigated through the Spearman’s test after normality
evaluation with the Shapiro–Wilk test. Associations with
clinico-pathological features were explored by the
Mann-Whitney U or Kruskal-Wallis tests, as statistically
appropriate. For categorical variables, the chi-square test
was performed. Overall survival (OS) was defined as the
time between breast cancer diagnosis and death for any
cause. Event free interval (EFI) was defined as the time be-
tween breast cancer diagnosis and local or distant relapse.
The prognostic impact of the variables taken into consid-
eration was investigated in the subset of patients that were
not diagnosed with de novo metastatic disease. The cumu-
lative incidence method was used to estimate EFI account-
ing for the presence of death as competing risks. Based on
the method of Fine and Gray (1999), univariate
competing-risk regression was used to explore which fac-
tors were associated with EFI. This model is based on the
hazard of the subdistribution and provides a simple rela-
tionship between covariates and cumulative incidence
[73]. OS was described according to the Kaplan-Meier ap-
proach. Univariate Cox regression was used to estimate
which factors were associated with OS. Statistical analysis
was conducted using the StataCorp 2016 Stata Statistical
Software: Release 14.2 (College Station, Texas, USA).
Immunohistochemistry analysis
Formalin-fixed and paraffin embedded breast cancer tis-
sues from core biopsies or nodulectomies were immuno-
histochemically stained using the peroxidase/DAB Plus
Dako REAL TM EnVision TM Detection System (Dako
A/S, Glostrup, Denmark). Heat induced retrieval of anti-
gen epitopes was carried out in a water bath at 98 °C
with 0.01M sodium citrate buffer (pH 6.0) for 30 min.
All primary antibodies were incubated for 60 min at RT.
The following mouse monoclonal primary antibodies
were used: APE1 (13B8E5C2 – Novus Biological 1/200
diluted) and NPM1 (FC-61991 – ThermoFisher Scien-
tific 1:50 diluted). Positive and negative controls for each
marker were included in each staining run according to
the supplier’s data sheet. Immunostaining was semi-
quantitatively evaluated by using light microscopy and
by scanning the entire section at high-power magnifica-
tion (× 400). Staining localization (nuclear and cytoplas-
mic) was scored in parallel leading to the determination
of the percentage of nuclear positive cells and the per-
centage of cytoplasmic positive cells. For NPM1, nucle-
olar localization was also recorded.
The cancer genome atlas gene expression analysis
We queried the cBioPortal for Cancer Genomics [74, 75]
using the cgdsr package (Jacobsen 2018) [76] inside the
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R/Bioconductor environment (R Core Team 2017) [77].
Starting from all the available cancer studies (n = 169,
Version 1.11.3), we focused on those that had RNA-seq
data available (n = 36). We recovered the relative expres-
sion of APE1 and NPM1, expressed in terms of Z-score,
for all the patients profiled in every examined cancer
study. Afterwards, we used the stats package to calculate
the Pearson correlation coefficient between paired sam-
ples and the associated p-values. Finally, we used the
graphics package to draw a barplot summarizing the
trend of statistically significant (p ≤ 0.05) correlations.
Clinical data for TNBC patients from the TCGA-BRCA
dataset was obtained using the FirebrowseR R package
[78]. Patients with an overall survival above/below five
years were identified, as well as those that did or did not
undergo disease recurrence after at least one year from
diagnosis. For every group of patients, genes having
positive or negative correlation (ρs ≥ + 0.5 or ρs ≤ − 0.5,
p ≤ 0.05) with both APE1 and NPM1 gene expression
levels were selected and functionally characterized.
Functional analysis
Gene signatures having positive or negative correlation
with APE1/NPM1 were functionally characterized using
the Cytoscape plugin ClueGO [79, 80] querying the fol-
lowing functional and metabolic databases: CLINVAR_
Human-diseases, WikiPathways, KEGG, CORUM-
FunCat-MIPS, REACTOME (“Reactions” and “Path-
ways”) and Gene Ontology (“Biological Process” and
“Immune System Process”, Min GO Level = 4 and Max
GO Level = 8). A right-sided hypergeometric test (cor-
rected using the Benjamini-Hochberg method to control
the false discovery rate) was applied to find enriched
terms (adjusted p ≤ 0.05). Related terms sharing similar
associated genes were fused to reduce redundancy.
Results
APE1 and NPM1 proteins protect from CDDP-induced
cytotoxicity in different cell line models
We first checked the contribution of the APE1 and
NPM1 proteins towards CDDP-induced cell cytotoxicity
by using APE1- and NPM1-knockout (KO) cell lines.
Specifically, we took advantage of CH12F3 cells express-
ing APE1 (CH12F3 APE1+/+/Δ) and the isogenic KO
(CH12F3 APE1Δ/Δ/Δ) [72, 81]. Dose response experi-
ments with CDDP (Fig. 1a) clearly demonstrated that
CH12F3 APE1Δ/Δ/Δ cells are significantly more sensitive
to the treatment than the isogenic control cells express-
ing APE1. Similarly, in order to test the effect of NPM1
on CDDP-induced cytotoxicity, we used the MEF cells
expressing (NPM1+/+) or not (NPM1−/−) NPM1 [41, 53,
71]. Again, the expression of NPM1 prevents CDDP-
induced cytotoxicity, thus exerting a protective function
(Fig. 1b). Finally, in order to evaluate the role of a
functional interaction of APE1/NPM1 on CDDP-
induced cytotoxicity, we used the OCI-AML3 cells char-
acterized by the expression of a haploinsufficient form of
the NPM1 protein, called NPM1c+, which aberrantly lo-
calized into the cytoplasm. NPM1c + is also associated
with a functional impairment of APE1, as a consequence
of APE1 aberrant subcellular distribution [41]. By treat-
ing OCI-AML3 cells with CDDP, and by comparing their
viability with the wild type counterpart OCI-AML2, we
clearly observed a significant higher sensitivity of the
NPM1c + expressing cell line with respect to the normal
isogenic control. All these data demonstrate that, not
only the presence of APE1 and NPM1, but also their
functional interaction, plays a major role in protecting
tumor cells from CDDP-induced cytotoxicity (Fig. 1c).
Differential sensitivity of TNBC cells to platinum salts
depends on NPM1 expression and involves cell-type
specific effects on the APE1/NPM1 proteins
Two different TNBC cell lines (HCC70 and HCC1937)
were chosen as a model for this study, based on their
different mutational status of the TP53 and BRCA1
genes, two important players in the response to Pt-salts
[82, 83]. First, basal levels of APE1 and NPM1 proteins
were analyzed in both cell lines. Western blotting ana-
lysis revealed that HCC1937 cells were characterized by
little though significantly higher (less than two folds)
protein levels of APE1 (Fig. 2a) and significantly higher
(more than five folds) levels of NPM1 (Fig. 2b) than
HCC70 cells. Based on the difference of APE1 and
NPM1 protein levels, we evaluated the effect of Pt-
compounds on cell survival. We performed a survival
assay, upon treatment with CDDP or CBDCA for differ-
ent time points (Fig. 3 and Table 1). Specifically, as
shown in Fig. 3a, b, both cancer cell lines were sensitive
to CDDP after 24 h of treatment. However, their re-
sponse was markedly different and was in agreement
with the expression levels of the APE1 and NPM1 pro-
teins; indeed, HCC1937 cells resulted more resistant to
CDDP (range 0–100 μM) (Fig. 3b) than HCC70 cells,
which were highly sensitive in the 0–12.5 μM range of
treatment (Fig. 3a). In the case of CBDCA-treatment, we
did not observe any major cytotoxicity after 24 h of
treatment (Fig. 3c, d). However, both cell lines showed a
significant decrease in survival upon 48h of treatment
(red lines in Fig. 3 c, d). As previously observed with
CDDP, HCC70 cells were particularly sensitive to the
treatment, showing a mortality that reached 60% (SD ±
0.041) at a dose of 100 μM. On the other hand,
HCC1937 cells were consistently less sensitive to
CBDCA, showing only 40% (SD ± 0.062) mortality at the
same dose of treatment. Taken together, these data sug-
gest that the two analyzed TNBC cell lines are differen-
tially responsive to Pt-salts, coherently with the different




Fig. 1 APE1 and NPM1 are involved in the response to CDDP cytotoxicity. a Representative western blotting on whole cell extracts (WCE) of
CH12F3 cells shows the different amount of APE1 in CH12F3 APE1+/+/Δ and the isogenic knock out CH12F3 APE1Δ/Δ/Δ. On the right side of each
panel, the Molecular Weights (MW), expressed in kDa, are indicated. On the left side of each panel, specific antibodies used in the
immunoblotting are indicated. Actin was used to normalize APE1 levels. Histograms show the decreased viability of both cell lines treated with
the indicated doses (μM) of CDDP for 24 h. Values express the mean viability ± SD from at least three independent replicates. Each value is
normalized to the untreated condition. ***p < 0.001. b Representative western blotting on whole cell extracts (WCE) of MEF cells shows the
different amount of NPM1 in MEF NPM1+/+ and the isogenic knock out MEF NPM1−/−. On the right side of each panel, the Molecular Weights
(MW), expressed in kDa, are indicated. On the left side of each panel, specific antibodies used in the immunoblotting are indicated. Actin was
used to normalize NPM1 levels. Histograms show the decreased viability of both cell lines treated with the indicated doses (μM) of CDDP for 24
h. Values express the mean viability ± SD from at least three independent replicates. Each value is normalized to the untreated condition. *p <
0.05, **p < 0.01, ***p < 0.001. c Representative western blotting on whole cell extracts (WCE) of OCI-AML cells shows the presence of NPM1c + in
OCI-AML3 compared to the counterpart OCI-AML2. On the right side of each panel, the Molecular Weights (MW), expressed in kDa, are indicated.
On the left side of each panel, specific antibodies used in the immunoblotting are indicated. Actin was used to normalize APE1 levels. Histograms
show the decreased viability of both cell lines treated with the indicated doses (μM) of CDDP for 24 h. Values express the mean viability ± SD
from at least three independent replicates. Each value is normalized to the untreated condition. ***p < 0.001
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expression levels of both APE1 and NPM1 proteins. In
particular, HCC70 cells resulted much more sensitive to
Pt-compounds than HCC1937 cells. For this reason, we
tested the protective activity of NPM1 in HCC70 cells
by overexpressing NPM1 by using a cell transfection ap-
proach, with a plasmid encoding for the wild type
flagged form of NPM1 (Fig. 3e-f ) [41]. The obtained data
clearly demonstrated that the NPM1 overexpression in
HCC70 cells (Fig. 3e) significantly decreased their
sensitization to CDDP treatment, in agreement with the
data obtained with the KO cell models and thus con-
firming the protective function of NPM1 towards
CDDP treatment (Fig. 3f ). Moreover, since the nucle-
olar presence and shuttling of the APE1 and NPM1
proteins might be used as markers of nucleolar stress
and of cellular response to CDDP, as previously re-
ported [43], we investigated the phenomenon in both
TNBC cell lines. As expected, APE1 and NPM1 pro-
teins re-localized from nucleoli into the nucleoplasm
compartment upon Pt-salts treatment. Remarkably, the
kinetics of shuttling was different among the two cell
lines, with a more prolonged time of nucleolar APE1
emptying in HCC1937 cells compared to HCC70 cells,
probably due to their different response to CDDP and
CBDCA treatments (Additional file 2: Figure S1 and
Additional file 3: Figure S2). In order to further investi-
gate the behavior of NPM1 and APE1 localization upon
treatment with Pt-salts, we also analyzed the effect on
the total amount of APE1 and NPM1 proteins. After a
low dose treatment with both Pt-compounds, HCC70
cells showed an increase of NPM1 expression up to
two-fold of the basal levels, independently from the
duration of the treatment (Fig. 4a-c and Additional file 4:
Figure S3). On the contrary, no changes in APE1 ex-
pression were apparent upon CDDP and CBDCA treat-
ments (data not shown). Notably, HCC1937 cells did
not show any significant alterations either in NPM1 or
APE1 (Fig. 4d-e and not shown). Therefore, the NPM1
protein resulted to be up-regulated by treatment with
Pt-compounds in HCC70 cells, only. On the other
hand, APE1 protein levels were apparently unaffected
by CDDP and CBDCA treatments in both TNBC cell
lines. Altogether, these data clearly suggest that the dif-
ferential sensitivity of TNBC cell lines to Pt-salts de-
pends on NPM1 expression and involves cell-type
specific effects on APE1/NPM1 proteins.
A B
C D
Fig. 2 HCC1937 cells show increased levels of APE1 and NPM1 proteins compared to HCC70 cells. Representative western blotting on whole cell
extracts of TNBC cells shows the amount of APE1 (a, b) and NPM1 (c, d) proteins. On the right side of each panel, the Molecular Weights (MW),
expressed in kDa, are indicated. On the left side of each panel, specific antibodies used in the immunoblotting are indicated. Relative graphs (b,
d) report the difference of each protein, normalized on Actin, between the HCC70 (blue bar) and HCC1937 (red bar) cell lines.
**p < 0.01, ****p < 0.0001
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APE1-inhibition sensitizes TNBC cancer cells to Pt-salts
treatment
In order to address whether APE1 also plays a role in
CDDP-cytotoxicity of TNBC cells, we used a targeting
strategy with specific APE1 inhibitors. To this purpose,
we used several inhibitors of APE1; specifically, we
tested Compound #3, highly specific for inhibiting the
AP-endonuclease activity of APE1 [59], and three novel
drugs, Spiclomazine, Fiduxosin and SB206553, known to
interfere with the APE1/NPM1 interaction [61]. The
effect of Compound #3 on cell viability was initially
assessed, as a single agent, during both 24 h- and 48 h-
of treatment (Fig. 5 and Table 1). HCC70 cells resulted
more sensitive than HCC1937 cells to CDDP treatment
(Fig. 5a), in agreement with a lower expression of APE1
in the former cell line. Although the observed IC50 was
similar after 48 h for both cell lines (Fig. 5b and Table 1),
the cytotoxicity of Compound #3 was higher in HCC70
cells already upon 24 h of treatment (Fig. 5a). Then, we






Fig. 3 Characterization of the different cytotoxic effect of CDDP and CBDCA on TNBC cells. Dispersion graphs show the decreased viability of
HCC70 (a) and HCC1937 (b) cells when treated with the indicated doses (μM) of CDDP for 24 h. Graphs in (c) and (d) report the diminished
viability of HCC70 and HCC1937 cells, respectively, when treated with the indicated doses (μM) of CBDCA for 24 (blue line) and 48 (red line)
hours. e Western blotting on whole cell extracts of HCC70 cells transfected with the Flag-NPM1 plasmid and relative control (EMPTY) compared
to HCC1937 cells shows the amount of NPM1. On the right side of each panel, the Molecular Weights (MW), expressed in kDa, are indicated. On
the left side of each panel, specific antibodies used in the immunoblotting are indicated. f Histogram reporting the viability of HCC70 cells
overexpressing NPM1 upon CDDP treatment. Values express the mean viability ± SD from at least three independent replicates. Each value is
normalized to the untreated condition. ***p < 0.001
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salts treatments (Fig. 6). The experimental setting con-
sisted in a chronic co-treatment with CDDP and Com-
pound #3 for 24 h (Fig. 6a, b) and with CBDCA and
Compound #3 for 48 h (Fig. 6c and d). As summarized
in the histograms, HCC70 cells showed a significant
sensitization effect of Compound #3 on both CDDP
(Fig. 6a) and CBDCA (Fig. 6c) treatments. A Bliss ana-
lysis, performed on these data, confirmed the existence
of a synergistic effect of the two drugs on this cell line
(data not shown). On the contrary, such effect was not
observed with HCC1937 cells (Fig. 6b and d). Altogether,
these data demonstrate that the cytotoxic effect ob-
served by inhibiting the APE1-endonuclease activity is
dependent on the APE1 levels expressed by the two
TNBC cell lines tested, resulting more cytotoxic for
HCC70 than for HCC1937 cell lines. In agreement, the
inhibition of APE1-endonuclease activity sensitizes
TNBC cell lines to Pt-compounds treatment in an
APE1-dependent manner. Afterwards, the same experi-
mental setting was adopted when using APE1/NPM1 in-
hibitors, either as single agents or in combination with
both Pt-compounds. As shown in Fig. 7, the effect of
each drug, as single agent, was different between the two
TNBC cell lines upon 24 h (Fig. 7a and Table 1), 48 h
(Fig. 7b and Table 1) and 72 h (Fig. 7c and Table 1). Ini-
tially, we observed a high mortality in both cell lines
when treated with Spiclomazine, whereas less mortality
was observed when cells were treated with SB206553 or
Fiduxosin. We then performed viability assays on com-
bined treatments with Pt-compounds. A Bliss analysis,
performed on these data, confirmed the existence of an
additive effect of the APE1/NPM1 inhibitors on HCC70
cell line (data not shown), in agreement with the lower
APE1/NPM1 levels. Specifically, a high sensitization ef-
fect of Fiduxosin with CDDP and CBDCA at 48 and 72
h was observed (Fig. 8a, b and d-e, respectively). More-
over, an effect was also observed when a co-treatment
with SB206553 and CDDP was performed (Fig. 8c).
Other combinations between APE1/NPM1 inhibitors
and Pt-compounds did not sensitize HCC70 cells (Add-
itional file 5: Figure S4). In conclusion, APE1/NPM1 in-
hibitors resulted to be cytotoxic ‘per se’ independently
from the TNBC background. Interestingly, when used in
combination with Pt-salts, APE1/NPM1 inhibitors can
enhance the effect of crosslinking compounds in a spe-
cific TNBC background-dependent manner.
Characterization of APE1 and NPM1 in a real-world
clinical setting is consistent with preclinical models
Based on the observed significant relationship between
APE1 and NPM1 in TNBC cell lines and their protective
function towards Pt-compounds, we then checked the
expression levels of both APE1 and NPM1 proteins in a
real cohort of TNBC samples. Among the total popula-
tion of 111 consecutive TNBC patients, 7 had de novo
metastatic disease, while distant relapse was experienced
by 27 patients. Median follow-up was 64 months [range
6;168]. In non-de novo metastatic patients, estimate OS
at 12 and 60months was 98 and 76%. Cumulative inci-
dence at 12 and 60 months was 3.8 and 17.5%, respect-
ively. Further clinico-pathological characteristics are
summarized in Table 2. Expression levels and
localization of the NPM1 and APE1 proteins were ana-
lyzed through IHC, as described in the Methodological
section (Fig. 9a). Levels and localization of NPM1 were
not associated with the presence of nodal (p = 0.588) or
distant metastasis at baseline (p = 0.104). On the other
Table 1 List of IC50 values obtained for each TNBC cell type,
type of drug, and timing response
Cell line Drug Time (hr) IC50 (μM)
HCC70 CDDP 24 5.72
HCC1937 29.6
HCC70 CBDCA 24 n.d. (> 100)
48 85.4
HCC1937 24 n.d. (> 100)
48 n.d. (interp = 171)
HCC70 Compound #3 24 2.96
48 3.17
HCC1937 24 n.d. (interp = 6)
48 3.09
HCC70 Fiduxosin 24 n.d. (> 20)
48 n.d. (> 20)
72 n.d. (> 20)
SB206553 24 n.d. (interp = 159)





HCC1937 Fiduxosin 24 n.d. (> 20)
48 n.d. (> 20)
72 n.d. (> 20)
SB206553 24 93.1





The analysis carried on by using the Combenefit 2.021 software allowed to
calculate the IC50 values for each drug tested on the two analyzed TNBC and
for different time points. n.d. means that the goodness of fit value is too low
or a standard Hill equation does not correctly account for the specific agent
used. In some cases, the expected interpolated IC50 value has been reported
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hand, significantly lower levels of total NPM1 were
found in tumors with a pT3 or pT4 stage (p = 0.046)
and among patients who developed distant metastases
during their whole clinical history (p = 0.011). Levels
and localization of APE1 and NPM1 were then analyzed
in order to explore potential in vivo correlations. NPM1
levels were significantly higher (p < 0.001) when the
nucleolar localization of NPM1 was absent, a similar
trend being observed also for the nuclear levels of APE1
(nAPE1) (p = 0.069). Higher levels of NPM1 were signifi-
cantly correlated with higher levels of nAPE1 (p < 0.001),
but not with cytoplasmic APE1 (cAPE1) (p = 0.119). On
the other hand, high levels of cAPE1 were significantly






Fig. 4 Chronic treatment with Pt-compounds induces an increase of NPM1 in HCC70 cells. a Representative western blotting shows the NPM1
protein levels trend in HCC70 cells, chronically treated with CDDP and CBDCA at the indicated concentration for different time-points, as
specified on the top of the panel. On the right side of each panel, the Molecular Weights (MW), expressed in kDa, are indicated. On the left side
of each panel, specific antibodies used in the immunoblotting are indicated. b, c Histograms reporting the quantitative values corresponding to
NPM1 protein amounts upon different time points of CBDCA (b) and CDDP (c) treatment compared to the basal untreated conditions and
normalized on β-tubulin. Values express the mean viability ± SD from at least three independent replicates. *p < 0.05, **p < 0.01. d, e
Representative western blotting shows the NPM1 protein levels trend in HCC1937 cells, chronically treated with CDDP (d) and CBDCA (e) at the
indicated concentration for different time-points, as specified on the top of the panel. On the right side of each panel, the Molecular Weights
(MW), expressed in kDa, are indicated. On the left side of each panel, specific antibodies used in the immunoblotting are indicated
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A B
Fig. 5 APE1 - inhibitor Compound #3 is differentially toxic in TNBC cell lines. Dispersion graphs show the decreased viability of HCC70 (blue line)
and HCC1937 (red line) cells when chronically treated with the indicated doses (μM) of Compound #3 for 24 h (a) or 48 h (b). Values express the
mean viability ± SD from at least three independent replicates. Each value is normalized to the untreated condition
A B
C D
Fig. 6 Compound #3 sensitizes only HCC70 cells to Pt-compounds treatment. Histograms show the effect of co-treatments with CDDP (a, b) or
CBDCA (c, d) and Compound #3 on viability of HCC70 (a-c) and HCC1937 (b, d) cells. Values express the mean viability ± SD from at least three
independent replicates. Each value is normalized to the untreated condition. *p < 0.05, **p < 0.01, ***p < 0.001. A Bliss analysis, performed on
these data, confirmed the existence of a synergistic effect of Compound #3 and Pt-salts on HCC70 cell line (data not shown)
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(p < 0.001). A differential association between APE1
localization and NPM1 levels was also observed when
dichotomization at 50% was applied for NPM1 (Fig. 9b).
NPM1 is associated with EFI in anthracycline-naïve patients
The role of NPM1 was further explored with respect to
prognosis. In the whole population, no associations were
observed in terms of EFI (SHR: 1.43, 95% C.I. 0.69–3.02,
p = 0.334). Consistent results were observed in terms of
OS (Table 3) (Fig. 10a, b). A subgroup analysis was then
performed in terms of EFI (Fig. 10c) and OS (data not
shown) for hypothesis generation. Notably, in patients
that were not treated with anthracyclines, low levels of
NPM1 were associated with a worse prognosis in terms
of EFI (SHR: 6.5, 95% C.I. 1.4–30.18, p = 0.017), but not
of OS (data not shown).
Identification of APE1/NPM1-related gene signatures in
TCGA-BRCA tumors
In order to generalize our findings and to investigate the
APE1 and NPM1 overall influence and association with
specific gene-signatures on tumorigenesis, we then
followed a more global approach using the available can-
cer datasets from TCGA. Using the cgdsr R/Bioconduc-
tor package, we analyzed all the TCGA datasets
associated with RNA-seq data (n = 36) and measured, on
a per sample basis, the correlation existing between
APE1 and NPM1 gene expression, represented by the
mRNA median z-scores of every patient (Additional file 6:
Figure S5). Out of twenty-five datasets (Table 4), in
which a significant correlation was obtained, Prostate
Adenocarcinoma and Bladder Urothelial Carcinomas
were the two having the highest and the lowest values
(p = 0.64 and p = 0.24, respectively), with Breast Invasive
Carcinoma showing a quite weak correlation (p = 0.28,
Fig. 11a). We then wondered if APE1 and NPM1 could
indirectly affect disease recurrence and overall survival,
by acting through the involvement of co-expressed genes
that could be functionally associated with tumorigenesis.
For this reason, we specifically examined TCGA-BRCA
TNBC patients, focusing on three different subsets: pa-




Fig. 7 APE1/NPM1 interaction inhibitors are differentially toxic in TNBC cell lines. Dispersion graphs show the decreased viability of HCC70 (blue
line) and HCC1937 (red line) cells when chronically treated with the indicated doses (μM) of APE1/NPM1 interaction inhibitors for 24 h (a), 48 h
(b) and 72 h (c). Values express the mean viability ± SD from at least three independent replicates. Each value is normalized to the
untreated condition
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five years, and patients that experienced tumor recur-
rence after at least one year from diagnosis (n = 23). For
each group of patients, we first defined the genes having
positive (ρs ≥ + 0.5, p ≤ 0.05) or negative correlation (ρs ≤
− 0.5, p ≤ 0.05) with either APE1 or NPM1 gene expres-
sion and, afterwards, we looked for co-occurrences be-
tween the different gene lists. Surprisingly, all the
common genes were always positively or negatively cor-
related with both APE1 and NPM1. In particular, APE1/
NPM1 showed positive or negative correlation with
twenty-four and eleven genes, respectively, in patients
having OS ≥5 years, and with thirty and seven genes, re-
spectively, in patients having OS < 5 years
(Additional file 7: Figure S6A). Moreover, patients ex-
periencing tumor recurrence, after at least one year from
diagnosis, had fifty-four genes that were positively corre-
lated with APE1/NPM1, while sixty-one had negative
correlation (Additional file 7: Figure S6B). An additional
Excel file contains the complete lists of positively and
negatively APE1/NPM1 correlated genes [see Add-
itional file 1]. Finally, these signatures were functionally
characterized using the Cytoscape plugin ClueGO,
querying several functional and metabolic databases.
Among the significantly enriched results (adjusted p ≤
0.05), we found terms pointing to mRNA processing and






Fig. 8 The Fiduxosin and SB206553 APE1/NPM1 interaction-inhibitors sensitize only HCC70 cells to platinum compounds treatment. Histograms
show the effect of co-treatments with CDDP (a, c, d) or CBDCA (b-e, f) and APE1/NPM1 inhibitors including Fiduxosin (a, b, d, e) and SB206553
(c), on HCC70 cells viability. Analysis was carried on for 48 h of treatment (a,b,c) or 72 h of treatment (d, e). Values express the mean viability ± SD
from at least three independent replicates. Each value is normalized to the untreated condition. *p < 0.05, **p < 0.001, ***p < 0.0001. A Bliss
analysis, performed on these data, confirmed the existence of an additive effect of the APE1/NPM1 inhibitors on HCC70 cell line (data not shown)
Malfatti et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:309 Page 13 of 23
could be the targets of new precision medicine
approaches.
Discussion
Pt-salts represent a common chemotherapeutic option
for the treatment of several tumors, including breast
cancer. Based on the evidences regarding the role of
BER factors in regulating Pt-salts cytotoxicity, and in
order to shed more light on the molecular basis of BER
protective function to Pt-compounds treatment, the
present study was aimed at characterizing the functional
relationship between APE1 and NPM1, as well as their
interaction with Pt-compounds. We focused specifically
on TNBC, a particularly aggressive tumor subtype, char-
acterized by poor prognosis and lack of novel thera-
peutic targets [11, 84], in which, currently, genotoxic
agents are gaining momentum as an important option
[15]. The genotoxic effect of Pt-salts, generating bulky
lesions on DNA, can be efficiently opposed by different
DNA repair pathways, including NER, HR and FA. Only
recently, BER has emerged as a putative DNA repair
pathway involved in cancer cell resistance to Pt-salts
treatments. However, the way in which BER is involved
still remains object of study. It has been demonstrated
that Pol β [85] could be considered a prognostic factor
in colorectal and esophageal cancer, for its ability to
affect Pt-salts susceptibility [63, 86, 87]. Similarly, APE1,
which is overexpressed in lung cancer, is directly in-
volved in CDDP resistance and its inhibition sensitizes
cancer cells to the treatment [68]. Conflicting observa-
tions were reported by Kothandapani et al., which have
hypothesized that BER could play a role in mediating the
CDDP cytotoxicity, showing how a BER blockage,
through Pol β or UNG1 knockout or treatment with
Methoxyamine, an indirect inhibitor of APE1 endo-
nuclease activity, may result in an increased resistance
to CDDP treatment [20, 21]. What is actually unclear is
why BER could be directly involved in the CDDP- in-
duced DNA damage, since it is not able to process any
bulky DNA distortion produced by Pt-induced adducts.
Interestingly, several authors have hypothesized an indir-
ect involvement of BER in mediating cisplatin cytotox-
icity [64, 65]. Again, Kothandapani et al. showed that
CDDP-treatment induces abasic sites accumulation close
to ICLs [20]. It also seems that CDDP and, to a lesser
extent, CBDCA and oxaliplatin may cause the gener-
ation of reactive oxygen species (ROS), significantly in-
creasing oxidative stress levels. Moreover, interesting
findings have recently shown how Pt-salts may incre-
ment ROS and DNA oxidation, leading to an increased
cell death [64], and have suggested a possible use of
APE1 redox inhibitors for the treatment/prevention of
secondary effects like Pt-induced sensory neuropathy
[88]. A further hypothesis regards the emerging discov-
eries about the non-canonical roles of BER proteins such
as those associated with RNA metabolism [23], that
could also explain the role of BER in Pt-salts induced ef-
fects. In fact, a strong but not completely characterized
association between Pt-salts and RNA-damage, which
inhibits ribosomal RNA synthesis in vivo [89] and
mRNA translation in vitro [90], has been found.
In this study, by using APE1- or NPM1-defective iso-
genic cell lines, we first demonstrated a leading role of
APE1 and NPM1 expression, as well as their functional
interaction, accounting for cell resistance to CDDP cyto-
toxicity. Then, by using two TNBC cell lines (HCC70 and
HCC1937 cells) characterized by a different p53- and
BRCA1-status, we initially categorized their response to
Pt-salts (CDDP and CBDCA) in vitro. Specifically, we ob-
served that HCC70 cells, having lower levels of both
APE1 and NPM1 proteins, were more sensitive to Pt-salts
treatments compared to HCC1937 cells; in particular, we
found that this occurred in a NPM1-dependent manner,
as demonstrated by the protective effect due to the over-
expression of NPM1 in the HCC70 cell line. In order to
evaluate whether APE1 was also involved in the response
Table 2 Demographic characteristics of the study populations.
IQR: interquartile range; AR: androgen receptor nAPE1: nuclear
APE1; cAPE1: cytoplasmic APE1
Categorical variables
Variable (N) Frequency (%)
Grading (99) 1 1 (1%)
2 24 (24%)
3 74 (75%)
Tumor size (92) 1 59 (64%)
2 27 (29%)
3 or 4 6 (7%)
Nodal status (91) Positive 39 (57%)
Negative 52 (43%)
De-novo metastatic (111) Yes 7 (6%)
No 104 (94%)
Neo/Adj Anthracyclines (104) Yes 74 (71%)
No 30 (29%)
Neo/Adj Taxanes (104) Yes 63 (61%)
No 41 (39%)
Continuous variables
Variable (N) Median IQR
Age at diagnosis (111) 57 38–83
Ki67 (84) 70 2–98
AR (111) 0 0–90
nAPE1 (111) 90 70–100
cAPE1 (111) 40 2.5–80
NPM1 (111) 70 40–90
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to Pt-salts in TNBC cells, we tested the effect of the com-
bination of CDDP and CBDCA with different APE1 inhib-
itors targeting the endonuclease activity of the protein
(e.g. Compound #3) and its interaction with NPM1
(Fiduxosin, Spiclomazine and SB206553) [59, 61]. After
evaluating the response of both TNBC cell lines to these
drugs as single agents, which demonstrated that the
HCC70 cell line was more sensitive to APE1-inibitors, in
agreement with the lower level of the protein with respect
to HCC1937, we analyzed the response of the combined
treatment with Pt-salts. Interestingly, we observed that
only HCC70 cells, expressing lower levels of both APE1
and NPM1, were sensitized by the combination of Com-
pound #3 or Fiduxosin with both crosslinking agents. We
previously reported that APE1 accumulates within the nu-
cleoli through the interaction with NPM1 [28]. Notably, in
that paper we observed that CDDP induced a re-
localization of both NPM1 and APE1 to the nucleoplasm
in HeLa cells and that impairment of the nucleolar-
nucleoplasmic shuttling kinetics of APE1 was associated
A
B
Fig. 9 NPM1 IHC expression is associated with APE1 localization. Representative IHC samples of TNBC tumors, obtained at 20X and 40X
magnification, revealing levels and localization of NPM1 and APE1 (a). Relative graph of nuclear vs cytoplasmic APE1 levels according to NPM1
(b). *** p < 0.0001 using the Mann-Whitney U test
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with a higher sensitivity to CDDP induced cytotoxicity
[43]. Our present data in TNBC cell lines, showing nucle-
olar emptying upon Pt-salts treatment but having different
kinetics between HCC70 and HCC1937 cell lines, allow to
conclude that APE1 and NPM1 proteins re-localization
from nucleoli to nucleoplasm after treatment with Pt-
compounds is a general phenomenon of cancer cells, even
though with different kinetics. The molecular mechanisms
at the basis of this phenomenon should be better clarified,
as well as their biological significance and relevance for
cancer therapeutics, and work is actually ongoing in our
laboratory along these lines. In order to explore the trans-
lational and clinical relevance of our results, we explored
the mutual interactions of APE1 and NPM1 and their as-
sociations with clinico-pathological features in a real-
world cohort of TNBC patients. Both APE1 and NPM1
biomarkers were analyzed using a healthcare-grade analyt-
ical pipeline, without any ad-hoc adaptations, rendering
this approach scalable and integrable with the current
clinical workflow. Moreover, expression level correlations
and localization associations were consistent with those
observed in our preclinical models. Notably, APE1 was
not associated with any common clinical characteristics,
while NPM1 was associated with worse disease onset and
interesting results were observed in the exploratory out-
come analysis, in terms of both protein levels and
localization. On the other hand, NPM1 failed to show a
prognostic role for the total population; however, the sub-
group analysis highlighted a potential role in terms of EFI
among patients not treated with anthracyclines in the neo-
adjuvant or adjuvant setting, suggesting that anthracycline
naïve patients with low NPM1 have a significantly higher
probability of having a local or distant relapse. Since
NPM1 has a pivotal role in controlling ribosomal biogen-
esis and genome stability [91], these data are an intriguing
hint in refining patients’ stratification according to poten-
tial response to genotoxic agents. As the anthracycline-
based regimen seems to bridge the gap between the
NPM1 low and high groups, these data suggest that there
is a subgroup of TNBC patients that not only is potentially
prone to respond, but that could be burdened by a worse
outcome if different therapeutic strategies were put in
place. These results are of particular clinical interest since
DNA-damaging strategies are an emerging opportunity
for the treatment of TNBC, but a solid predictive marker
is currently needed [12, 17, 92]. The inability to translate
this difference on OS could be due to the small sample
size, post-relapse treatments or underlying differences in
terms of tumor biology. In order to further elucidate this
aspect, we investigated the overall impact of APE1 and
NPM1 levels through TCGA-derived RNA-seq data. To
find promising companion proteins, based on the hints
derived by our clinical results, we then compared patients
with an OS lower or higher than 5 years, and those with a
recurrence after at least 1 year from diagnosis and we
identified subsets of genes (Additional file 7: Figure S6)
that positively or negatively correlated with APE1 and
NPM1 levels. Interestingly, the functional terms associated
with these signatures highlighted biological processes that
could represent new hubs for personalized anti-cancer
treatments. We found of particular interest the alterations
concerning cell-cycle dependent proteins observed among
Table 3 Univariate analysis in terms of OS (overall survival) and
EFI (event free survival) with correction for competing risks and
on the total population
Variable SHR 95% C.I. p value
EFI
NPM1 Continuous 0.99 0.98–1.00 0.147
NPM1 nucleolus No 1
Yes 1.83 0.79–4.27 0.161
NPM1 with cut-off > 50% 1
≤50% 1.43 0.69–3.02 0.334
nAPE1 Continuous 0.99 0.98–1.00 0.344
cAPE1 Continuous 1.01 0.99–1.02 0.149
Tumor size 1 1
2 1.35 0.58–3.14 0.491
3 or 4 3.48 0.79–15.44 0.100
Nodal status Negative 1
Positive 2.05 0.92–4.58 0.079
Neo/Adj Anthracyclines No 1
Yes 1.06 0.47–2.39 0.886
Neo/Adj Taxanes No 1
Yes 0.82 0.39–1.69 0.585
OS HR 95% C.I. p value
NPM1 nucleolus No 1
Yes 1.37 0.59–3.20 0.464
NPM1 with cut-off > 50% 1
≤50% 1.25 0.61–2.57 0.541
nAPE1 Continuous 1 0.99–1.01 0.767
cAPE1 Continuous 1 0.99–1.01 0.553
Tumor size 1 1
2 1.73 0.73–4.11 0.214
3 or 4 12.59 4.30–36.84 < 0.001
Nodal status Negative 1
Positive 1.47 0.68–3.17 0.328
Neo/Adj Anthracyclines No 1
Yes 0.45 0.22–0.91 0.026
Neo/Adj Taxanes No 1
Yes 0.50 0.24–1.02 0.055
Tumor size was confirmed as the most important prognostic factor. nAPE1
(nuclear APE1), cAPE1 (cytoplasmic APE1) NPM1 (NPM1low vs NPM1high), HR
(hazard ratio), SHR (subdistribution hazard ratio)
Malfatti et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:309 Page 16 of 23
patients with an OS < 5 years. Targeting cell cycle is a new
emerging strategy that was particularly effective in
luminal-like breast cancer in reverting endocrine resist-
ance [93], but interesting data suggest a possible role of
CDK4–6 inhibitors also as chemo-companions, since
CDK6 may interfere with Pt-induced cell death through
FOXO3 [94]. The present study, therefore, supports the
rationale of finding optimal DNA-repair - focused com-
panions, capable to both synergize with chemotherapy
and to revert potential resistance mechanisms that could
defeat the DNA - damaging potential of Pt-salts [12]. Syn-
thetic lethality involving the inhibition of the APE1 endo-
nuclease activity is only recently emerging in literature
[95, 96]. The differential response of the TNBC cell lines
here tested is certainly interesting, as it could be helpful in
understanding TNBC heterogeneity and consequently
tailor the right therapeutic associations and sequences on
the single patient. This possibility is currently under inves-
tigations in our laboratory, but it is likely that the different
mutational status of p53 could have a role in the observed
differences. As reported in the Materials and Methods
section, the mutational status of TP53 is different among
the two TNBC cell lines used in the present study. The
R248Q mutation, occurring in HCC70 cells, represents a
“hot spot” mutation in the DNA binding domain (DBD)
of the transcription factor (amino acids 109–288), often
found in several types of tumors. This mutation belongs
to the class of mutagenic p53 that affects the DNA bind-
ing activity without destabilizing the DBD [97, 98]. Gener-
ally, R248Q is a functional mutation of p53 that causes an
aberrant overexpression of the p53 protein [99]. Just re-
cently, Olszewski et al. have demonstrated that the R248
mutational status may affect cancer cell biology, in a cell-
type dependent manner, demonstrating how in breast can-
cer the expression of R248Q p53 decreases the motility
and invasiveness [100], differently from what has been
published in other tumors types [101, 102]. Contrarily to
the HCC70 cell line, the HCC1937 cells have an acquired
non-sense mutation (C306T) occurring on the TP53 gene
and giving rise to a conversion of a codon encoding for
R306 to a STOP codon, which occurs close to the tetra-




Fig. 10 Prognostic role of NPM1 in TNBC. Impact of NPM1 on the whole TNBC population using a 50% cutoff showed as Cumulative Incidence
(EFI) and Survival Probability (OS) (a, b). NPM1 subgroup analysis in terms of EFI according to tumor stage, nodal status and use of anthracyclines
or taxanes in adjuvant or neoadjuvant setting (c)
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causes a negative expression of p53 [103]. Data not shown
from our laboratory (Codrich et al., submitted) clearly
demonstrated that the inhibition of the APE1 endonucle-
ase activity by Compound #3, in different cancer cell lines
including HCC70 and HCC1937, causes a reduction of
cell viability in a p53-dependent manner, possibly involv-
ing nucleolar stress and impairment of ribosome biogen-
esis [43]. Based on these premises, the lack of sensitization
response of HCC1937 cells to the combined-treatment
with Pt-compounds and Compound #3 could indeed be
linked to a potential differential effect mediated by the
p53 functional status.
In the case of BRCA1 gene, which is important for
correct functional activity of HR in repairing DSBs
formation generated by Pt-compounds, it was some-
how surprising that HCC1937 cells (BRCA1-deficient),
see Materials and Methods section for details, were
more resistant to cisplatin than HCC70 cells (BRCA1-
proficient). We believe that, in the time-frame and
doses we considered in our experimental set up, the
effect on cell viability was not only due to a differ-
ence in the DNA repair activity by HR, by means of
BRCA1 functional protein, but also to damages asso-
ciated to RNA processing mechanisms, which are cor-
related with APE1/NPM1 functional activities.
Moreover, a major role of NHEJ in repairing DSBs in-
duced by Pt-compounds treatment by HCC1937 cell
line, cannot be excluded at present. Thus, further
studies are needed to drive definitive conclusions on
these hypotheses.
Conclusion
The present study analyzed the relevance of APE1,
NPM1 and their interaction towards Pt-salts cell cyto-
toxicity and explored their role as clinically transfer-
able biomarkers for patients’ selection and hypothesis
generation. APE1 and NPM1 protect cancer cells
from Pt-compounds cytotoxicity, suggesting a possible
improvement of the activity of Pt-based therapy for
TNBC, using the NPM1 and APE1 proteins as second
Table 4 Detailed description of TCGA tumor datasets having a statistically significant APE1/NPM1 gene expression correlation. Every
cohort is represented by its symbol (as shown in Additional file 6: Figure S5), full description, RNA-seq gene expression correlation
between APE1 and NPM1 and statistical significance of the data
Cohort Description Corr P value
PRAD Prostate adenocarcinoma 0.644 1.58E-59
KICH Kidney Chromophobe 0.590 1.88E-07
PAAD Pancreatic adenocarcinoma 0.517 1.41E-13
SARC Sarcoma 0.503 5.22E-18
GBMLGG Glioma 0.501 9.73E-44
THYM Thymoma 0.462 1.07E-07
LUAD Lung adenocarcinoma 0.448 8.68E-27
THCA Thyroid carcinoma 0.445 1.00E-25
KIPAN Pan-kidney cohort (KICH+KIRC+KIRP) 0.431 1.30E-41
KIRP Kidney renal papillary cell carcinoma 0.431 1.48E-14
STES Stomach and Esophageal carcinoma 0.415 2.24E-26
STAD Stomach adenocarcinoma 0.412 1.77E-18
ESCA Esophageal carcinoma 0.398 2.28E-08
KIRC Kidney renal clear cell carcinoma 0.392 5.52E-21
CESC Cervical squamous cell carcinoma and endocervical adenocarcinoma 0.380 7.13E-12
UCEC Uterine Corpus Endometrial Carcinoma 0.369 4.73E-19
LIHC Liver hepatocellular carcinoma 0.348 5.09E-12
COAD Colon adenocarcinoma 0.344 3.87E-14
GBM Glioblastoma multiforme 0.306 1.17E-04
COADREAD Colorectal adenocarcinoma 0.291 1.25E-13
BRCA Breast invasive carcinoma 0.282 1.74E-21
SKCM Skin Cutaneous Melanoma 0.270 5.76E-03
HNSC Head and Neck squamous cell carcinoma 0.264 1.04E-09
LUSC Lung squamous cell carcinoma 0.246 2.31E-08
BLCA Bladder Urothelial Carcinoma 0.244 6.14E-07
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therapeutic targets. We propose several TNBC gene
signatures having positive or negative correlation with
APE1 and NPM1. Of particular interest, APE1/NPM1
gene expression levels are associated with the alter-
ations concerning cell-cycle dependent proteins ob-
served among patients with an OS < 5 years.
Additional files
Additional file 1: Complete lists of negatively and positively APE1/
NPM1 correlated genes. Sheet A. List of APE1 (col. A-C) and NPM1 (col.
E-G) negatively or positively correlated genes (ρs≤ − 0.2 or ρs ≥ + 0.2,
respectively) in TCGA-BRCA patients with OS ≥5 years (n = 44). Columns
I-L contain the subset of genes having ρs≤ − 0.5 or ρs ≥ + 0.5, p ≤ 0.05
that underwent the functional analysis phase. Sheet B. Same as A, but for
patients that died after 5 or more years (n = 5). Sheet C. Same as A, but
for patients that were censored within 5 years (n = 108). Sheet D. Same
as A, but for patients with OS < 5 years (n = 23). Sheet E. Recapitulative
lists of genes from Sheet A and D that underwent the functional analysis
phase. Sheet F. Same as A, but for patients that experienced tumor
recurrence after at least one year from diagnosis (n = 23). (DOCX 26 kb)
Additional file 2: Figure S1. CDDP induces a nucleolar emptying of
APE1 and a nucleoplasmic re - localization of NPM1. (a, b)
Immunofluorescence staining for APE1 on HCC70 (a) and HCC1937 (b) cells
shows an evident nucleolar emptying of APE1 upon CDDP treatment
(3.125 μM) in a time-dependent trend. The nucleolar repopulation is
observed in HCC70 cells only, after 24 h of treatment. HCC1937 cells
responded differently, with a prolonged emptying of nucleolar APE1 that
persisted up to 72h of treatment. (c, d)Immunofluorescence staining for
NPM1 on HCC70 (c)and HCC1937 (d) cells shows an increased
accumulation of NPM1 into the nucleoplasmic compartment upon CDDP
treatment (3.125 μM) in a time-dependent trend. Yellow arrowheads
highlight representative cells showing the characteristic phenotype as
described. ‘Untreated’ corresponds to the condition in which the cells didn’t




Fig. 11 Comparison of APE1 and NPM1 gene expression levels and functional characterization of APE1/NPM1 correlated genes. Scatter plot
showing the relationship existing between APE1 and NPM1 expression levels in TCGA Breast Invasive Carcinoma patients (n = 1105). The red
dash-dotted lines represent the first and third quartile fits, the central dashed line represents the mean smooth and the green line represents the
fitted regression line (Ordinary Least Squares). Marginal boxplots are also shown (a). Two lists of genes with APE1/NPM1 correlated expression
(ρs≥ + 0.5 or ρs≤ − 0.5, p ≤ 0.05) were identified in two groups of TNBC patients having an OS higher (b, n = 44) or lower (c, n = 23) than 5
years. Functionally enriched terms (Benjamini-Hochberg adjusted p≤ 0.05) were identified using the Cytoscape plugin ClueGO, querying several
functional and metabolic databases, and results were summarized as pie charts. The same analysis was repeated on a group of patients (n = 23)
that had a relapse of the disease after at least one year from diagnosis, analyzing separately the gene signatures with positive (ρs≥ + 0.5, p≤
0.05, n = 54) or negative (ρs≤ − 0.5, p≤ 0.05, n = 61) correlation with APE1/NPM1 (d, e)
Malfatti et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:309 Page 19 of 23
staining was used to identify nuclei. ‘Merge’ indicates the overlapping of the
signals of APE1 (or NPM1) and TOPRO-3. (PDF 968 kb)
Additional file 3: Figure S2. CBDCA induces a nucleolar emptying of
APE1 and a nucleoplasmic re - localization of NPM1. (a, b)Immunofluorescence
staining for APE1 on HCC70 upon CBDCA treatment (100 μM)(a) and
HCC1937 upon CBDCA treatment (25 μM) (b)cells shows an evident
nucleolar emptying of APE1 in a time-dependent trend. The nucleolar
repopulation is observed in HCC70 cells only, after 24 h of treatment.
HCC1937 cells responded differently, with a prolonged emptying of
nucleolar APE1 that persisted up to 72h of treatment. (c, d) Immunofluorescence
staining for NPM1 on HCC70 upon CBDCA treatment (100 μM) (c)and
HCC1937 upon CBDCA treatment (25 μM) (d) cells shows an increased
accumulation of NPM1 into the nucleoplasmic compartment in a time-
dependent trend. Yellow arrowheads highlight representative cells showing
the characteristic phenotype as described. ‘Untreated’ corresponds to the
condition in which the cells didn’t undergo any treatment at the
corresponding longer point of time. TOPRO-3 staining was used to identify
nuclei. ‘Merge’ indicates the overlapping of the signals of APE1 (or NPM1)
and TOPRO-3. (PDF 999 kb)
Additional file 4: Figure S3. Chronic treatment with Pt-compounds
induces an increase of NPM1 on HCC70 cells. (a) (up) Representative
western blotting shows the NPM1 protein levels trend in HCC70 cells
treated with CDDP at different time points (right) or different
concentrations (left), as specified on the top of the panel. On the right
side of each panel, the Molecular Weights (MW), expressed in kDa, are
indicated. On the left side of each panel, specific antibodies, used in the
immunoblotting, are indicated. (bottom) Histograms reporting the
quantitative values corresponding to the NPM1 protein amounts
compared to the basal untreated conditions and normalized on Tubulin.
Values express the mean viability ± SD from at least three independent
replicates. *p < 0.05. (b) (up) Representative western blotting shows the
NPM1 protein levels in HCC70 cells, treated with CBDCA at different
concentrations or different time points, as specified on the top of the
panel. On the right side of each panel, the Molecular Weights (MW),
expressed in kDa, are indicated. On the left side of each panel, specific
antibodies, used in the immunoblotting, are indicated. (bottom)
Histograms reporting the quantitative values corresponding to the NPM1
protein amounts compared to the basal untreated conditions and
normalized on Tubulin. Values express the mean viability ± SD from at
least three independent replicates. *p < 0.05. (PDF 587 kb)
Additional file 5: Figure S4. Spiclomazine inhibitor does not sensitize
HCC70 cells to Pt-compounds treatment. Histograms show the effect of
co-treatments with CDDP (a, d, f) or CBDCA (b, c, e, g) and APE1/NPM1
inhibitors, Spiclomazine (a, b, d, e) and SB206553 (c, f, g)on HCC70 cells
viability. Values express the mean viability ± SD from at least three
independent replicates. Each value is normalized to the untreated
condition. (PDF 81 kb)
Additional file 6: Figure S5. Comparison of APE1 and NPM1 gene
expression levels in TCGA tumor datasets. Barplot summarizing the
statistically significant correlations (p ≤ 0.05) existing between APE1 and
NPM1 expression levels in twenty-five TCGA tumor samples. RNA-seq
data for thirty-six TCGA datasets were extracted and Pearson correlation
coefficients between APE1 and NPM1 were calculated on a per sample
basis, retaining and plotting only the statistically significant results. The
number of patients profiled in every dataset is shown on top of each bar;
bar colors reflect the size of the correlations. (PDF 96 kb)
Additional file 7: Figure S6. Venn diagrams showing similarities and
differences existing among the examined gene lists. Differences in
patients’ overall survival below or above 5 years allowed to identify four
gene signatures that positively or negatively correlated with both APE1
and NPM1 gene expression (a). Differences in disease recurrence after at
least one year from diagnosis defined several specific signatures as well
as two lists of genes that had a positive or negative correlation with both
APE1 and NPM1 gene expression (b). (PDF 105 kb)
Abbreviations
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